FDA grants Fast Track Designation for SPI-1005 in the Treatment of Meniere’s Disease -Sound Pharmaceuticals

SEATTLE, Sept. 18, 2019 /PRNewswire/ — Sound Pharmaceuticals is pleased to announce that the FDA’s Division of Neurology Products has granted its request for Fast Track Designation (FTD) involving SPI-1005 in the treatment of Meniere’s Disease (MD). FTD applies to serious conditions where the potential to address unmet medical need has been demonstrated. SPI’s clinical data from […]

Read More FDA grants Fast Track Designation for SPI-1005 in the Treatment of Meniere’s Disease -Sound Pharmaceuticals

Review of evidence on noninvasive vagus nerve stimulation for treatment of migraine -NCBI

Review of evidence on noninvasive vagus nerve stimulation for treatment of migraine: efficacy, safety, and implications. Mwamburi M1, Tenaglia AT2, Leibler EJ, Staats PS3. Author information Abstract GammaCore was cleared by the FDA for the acute treatment of episodic migraine and episodic cluster headache and has 5 Conformité Européenne marks. Data indicate that gammaCore treatment is both safe […]

Read More Review of evidence on noninvasive vagus nerve stimulation for treatment of migraine -NCBI